Author: Balaz, David; Wikman-Jorgensen, Philip Erick; Galvañ, Vicente Giner; Rubio-Rivas, Manuel; de Miguel Campo, Borja; López, Mariam Noureddine; Caleya, Juan Francisco López; Huelgas, Ricardo Gómez; Fontán, Paula MarÃa Pesqueira; Bailón, Manuel Méndez; Fernández-Garcés, Mar; Cruz, Ana Fernández; GarcÃa, Gema MarÃa GarcÃa; Rhyman, Nicolás; Corral-Gudino, Luis; RodrÃguez-Mancheño, Aquiles Lozano; De La Chica, MarÃa Navarro; GarcÃa, Andrea Torregrosa; Alcalá, José Nicolás; Jiménez, Pablo DÃaz; Trallero, Leticia Esther Royo; Casanova, Pere Comas; Núñez-Cortés, Jesús Millán; Casas-Rojo, José-Manuel
Title: Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry Cord-id: 7dn1rcrf Document date: 2021_10_8
ID: 7dn1rcrf
Snippet: Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020.
Document: Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7–160) vs. 49.3 (16–109) mg/dL; p < 0.001), ferritin (791 (393–1534) vs. 470 (236–996) µg/dL; p < 0.001), D dimer (750 (430–1400) vs. 617 (345–1180) µg/dL; p < 0.001), and lower Sp0(2)/Fi0(2) (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation
Search related documents:
Co phrase search for related documents- absolute value and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9
- absolute value and low mortality: 1
- absolute value and low mortality risk: 1
- absolute value and lung damage: 1
- active neoplasm and admission time: 1
- active neoplasm and logistic regression: 1
- admission time and local protocol: 1
- admission time and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- admission time and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- admission time and low mortality risk: 1, 2, 3
- admission time and lung damage: 1, 2, 3, 4
- local protocol and logistic regression: 1
Co phrase search for related documents, hyperlinks ordered by date